• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[使用溶组织梭菌胶原酶治疗掌腱膜挛缩症]

[Treatment of Dupuytren's disease using collagenase from Clostridium histolyticum].

作者信息

Martín-Ferrero M Á, Simón-Pérez C, Rodríguez-Mateos J I, García-Medrano B, Hernández-Ramajo R, Brotat-García M

机构信息

Servicio de Cirugía ortopédica y Traumatología, Hospital Clínico Universitario de Valladolid, Valladolid, España.

出版信息

Rev Esp Cir Ortop Traumatol. 2013 Nov-Dec;57(6):398-402. doi: 10.1016/j.recot.2013.07.005. Epub 2013 Sep 9.

DOI:10.1016/j.recot.2013.07.005
PMID:24071041
Abstract

OBJECTIVE

The collagenase from Clostridium histolyticum is a new therapeutic option, and the first pharmacological one, in the treatment of Dupuytren's disease.

MATERIAL AND METHODS

A prospective study was conducted on 35 patients with Dupuytren's disease. The clinical and functional variables, as well as patient satisfaction and drug safety were evaluated.

RESULTS

The functional and clinical results after its administration were good, with a rapid recovery, especially at the metacarpophalangeal (MCP) joint. The index finger contracture prior to MCP puncture was 64 degrees and after puncture it was 4 degrees. In the proximal interphalangeal (PIP) prior to puncture it was 83.3 degrees and after puncture it was 15 degrees; In the MCP/PIP prior to puncture it was 140 degrees, and after puncture it 25 degrees.

CONCLUSIONS

Collagenase from Clostridium histolyticum an alternative of treatment of Dupuytren's disease, mainly in the elderly. More research is required in order to clarify the rate of recurrence of the disease, the possible adverse reactions, and to compare the efficiency and permanence with other treatment options.

摘要

目的

溶组织梭菌胶原酶是治疗掌腱膜挛缩症的一种新的治疗选择,也是第一种药物治疗方法。

材料与方法

对35例掌腱膜挛缩症患者进行了一项前瞻性研究。评估了临床和功能变量,以及患者满意度和药物安全性。

结果

给药后的功能和临床效果良好,恢复迅速,尤其是在掌指关节处。掌指关节穿刺前食指挛缩为64度,穿刺后为4度。近端指间关节穿刺前为83.3度,穿刺后为15度;掌指关节/近端指间关节穿刺前为140度,穿刺后为25度。

结论

溶组织梭菌胶原酶是治疗掌腱膜挛缩症的一种替代方法,主要适用于老年人。需要更多的研究来阐明该疾病的复发率、可能的不良反应,并与其他治疗选择比较疗效和持久性。

相似文献

1
[Treatment of Dupuytren's disease using collagenase from Clostridium histolyticum].[使用溶组织梭菌胶原酶治疗掌腱膜挛缩症]
Rev Esp Cir Ortop Traumatol. 2013 Nov-Dec;57(6):398-402. doi: 10.1016/j.recot.2013.07.005. Epub 2013 Sep 9.
2
Injectable collagenase clostridium histolyticum for Dupuytren's contracture.注射用溶组织梭菌胶原酶治疗掌腱膜挛缩症
N Engl J Med. 2009 Sep 3;361(10):968-79. doi: 10.1056/NEJMoa0810866.
3
Efficacy and safety of collagenase treatment for Dupuytren's disease: 2-year follow-up results.胶原酶治疗掌腱膜挛缩症的疗效与安全性:2年随访结果
Hand Surg Rehabil. 2017 Oct;36(5):346-349. doi: 10.1016/j.hansur.2017.06.007. Epub 2017 Jul 18.
4
Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.注射用溶组织梭状芽孢杆菌胶原酶:一种治疗杜普伊特伦挛缩症的新型非手术疗法。
J Hand Surg Am. 2010 Dec;35(12):2027-38.e1. doi: 10.1016/j.jhsa.2010.08.007.
5
Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症近端指间关节的疗效及安全性:4项3期临床试验的综合分析
J Hand Surg Am. 2015 May;40(5):975-83. doi: 10.1016/j.jhsa.2015.02.018. Epub 2015 Apr 2.
6
[Collagenase Clostridum histolyticum in the management of Dupuytren's contracture].[溶组织梭菌胶原酶在掌腱膜挛缩症治疗中的应用]
Handchir Mikrochir Plast Chir. 2011 Oct;43(5):269-74. doi: 10.1055/s-0031-1286314. Epub 2011 Sep 20.
7
Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.溶组织梭状芽孢杆菌胶原酶注射治疗掌腱膜挛缩症的疗效与安全性:两项开放标签研究的短期结果
J Hand Surg Am. 2013 Jan;38(1):2-11. doi: 10.1016/j.jhsa.2012.10.008. Epub 2012 Dec 4.
8
Enzyme injection as nonsurgical treatment of Dupuytren's disease.酶注射作为掌腱膜挛缩症的非手术治疗方法。
J Hand Surg Am. 2000 Jul;25(4):629-36. doi: 10.1053/jhsu.2000.6918.
9
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.溶组织梭状芽孢杆菌胶原酶治疗后掌腱膜挛缩复发情况(CORDLESS [胶原酶用于掌腱膜挛缩减少的长期安全性评估研究]):5年数据
J Hand Surg Am. 2015 Aug;40(8):1597-605. doi: 10.1016/j.jhsa.2015.04.036. Epub 2015 Jun 18.
10
Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data.溶组织梭菌胶原酶治疗后杜普伊特伦挛缩复发(无绳研究):3年数据
J Hand Surg Am. 2013 Jan;38(1):12-22. doi: 10.1016/j.jhsa.2012.09.028. Epub 2012 Nov 30.

引用本文的文献

1
Clinical Outcomes of Collagenase Injections in Management of Dupuytren Contracture of the Proximal Interphalangeal Joint.胶原酶注射治疗近端指间关节掌腱膜挛缩症的临床疗效
J Hand Surg Glob Online. 2024 Jul 9;6(5):627-630. doi: 10.1016/j.jhsg.2024.05.009. eCollection 2024 Sep.
2
Long-term recurrence of Dupuytren's disease treated with clostridium histolitycum collagenase. Surgical treatment and anatomopathological study.胶原酶治疗的杜普伊特伦挛缩病的长期复发。手术治疗及解剖病理学研究。
Arch Orthop Trauma Surg. 2024 May;144(5):2085-2091. doi: 10.1007/s00402-024-05320-7. Epub 2024 Apr 23.
3
In Vitro Study of a Novel -Based Collagenase for Future Medical Application.
新型胶原酶的体外研究及其未来医学应用。
Cells. 2023 Aug 8;12(16):2025. doi: 10.3390/cells12162025.
4
Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.影响组织溶解性梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症复发和进展的因素。
Int Orthop. 2018 Apr;42(4):859-866. doi: 10.1007/s00264-017-3690-0. Epub 2017 Nov 23.
5
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:一项系统评价
Br Med Bull. 2016 Jun;118(1):149-58. doi: 10.1093/bmb/ldw020. Epub 2016 May 5.